Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.15% | 8.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.15% | 8.73% | |||
| Cost of Revenue | -1.73% | 5.84% | |||
| Gross Profit | -4.59% | 11.85% | |||
| SG&A Expenses | 0.80% | 7.77% | |||
| Depreciation & Amortization | -3.93% | 5.80% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.90% | 6.90% | |||
| Operating Income | -28.49% | 66.46% | |||
| Income Before Tax | -14.45% | 109.83% | |||
| Income Tax Expenses | -80.24% | 200.69% | |||
| Earnings from Continuing Operations | 104.39% | 57.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 104.39% | 57.91% | |||
| EBIT | -28.49% | 66.46% | |||
| EBITDA | -5.76% | 14.18% | |||
| EPS Basic | 104.29% | 57.96% | |||
| Normalized Basic EPS | 61.29% | -128.05% | |||
| EPS Diluted | 104.11% | 56.16% | |||
| Normalized Diluted EPS | 61.29% | -128.05% | |||
| Average Basic Shares Outstanding | -0.19% | 0.15% | |||
| Average Diluted Shares Outstanding | -0.19% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
